Clinical trial NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Official title: A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
Lead sponsor: Bio-Path Holdings, Inc.
Sponsor class: INDUSTRY
First posted: 2022-01-13
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).


Eligibility criteria: Inclusion Criteria:

1. Adults ≥18 years of age, with histologic evidence of refractory/relapsed AML who have failed treatment with available therapies known to be active for refractory/relapsed AML
2. Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1 or 2
3. For the dose expansion phase, participants with documented diagnosis of AML who are eligible for decitabine therapy
4. Participants must have adequate hepatic and renal functions as defined by:

   1. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN); and
   2. Usually total bilirubin ≤ 1.5 ULN. In specific cases the PI may request a waiver of this requirement with medical justification and agreement with the medical monitor and Bio-Path Holdings. And;
   3. Estimated creatinine clearance of at least 60 mL/min. These estimations are calculated using the Cockcroft-Gault equation.
5. Female participants of childbearing potential must agree to use an acceptable method of birth control (i.e. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of study drug or decitabine
6. Male participants must agree to use an acceptable method of contraception for the duration of the study
7. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
8. Participants must be willing and able to provide written informed consent

Exclusion Criteria:

1. Active non-hematologic or lymphoid malignancy other than AML treated with immunotherapy, targeted therapy or chemotherapy within the previous 12 months
2. Known, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Participants with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening
3. Isolated potentially treatable extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (for AML usually ≥ 5% blasts in BMA or biopsy). Participants may have leukemia with lower blast counts (Döhner 2017). Bio-Path Holdings and Investigator concurrence required.
4. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA
5. Chronic myeloid leukemia in any phase
6. Receipt of any anti-cancer therapy within 14 days prior to C1D1, with the exception of hydroxyurea or leukapheresis
7. Participants may not be receiving any other investigational agents
8. Female participants who are pregnant or breast-feeding
9. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
10. Participants with human immunodeficiency virus (HIV) infection who have CD4+ T-cell counts \< 350 cells/mcL or with clinically active hepatitis B or C infection
11. History of any hypersensitivity to hypomethylating agents, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor
12. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy or procedure, excluding alopecia
13. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline ECG abnormality (e.g., QTcF \>470 msec)
14. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
15. Uncontrolled seizure disorder (i.e., seizures within the past 2 months)
16. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason

Primary outcomes:
measure: Identify Dose Limiting Toxicity (DLT) of BP1002
timeFrame: 30 days
measure: Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002
timeFrame: 30 days
measure: Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002
timeFrame: 30 days
measure: Recommended Phase 2 (RP2D) of BP1002
timeFrame: 210 days
measure: Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration
timeFrame: 30 days
measure: Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution
timeFrame: 30 days
measure: Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant
timeFrame: 30 days
measure: Determine half-life plasma pharmacokinetics (PK) of BP1002
timeFrame: 30 days
measure: Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in ECG intervals) of escalating doses of BP1002
timeFrame: 30 days
measure: Determine pharmacodynamics (PD) of BP1002
timeFrame: 30 days
measure: Determine anti-drug antibody (ADA) levels of BP1002
timeFrame: 30 days
Secondary outcomes:
measure: Determine evidence of response by bone marrow aspirate
timeFrame: 180 days
measure: Determine evidence of response by complete blood counts using peripheral blood
timeFrame: 180 days
measure: Assessment of morphologic leukemia free state (MLFS) and partial remissions by bone marrow aspirate and complete blood counts
timeFrame: 180 days
measure: Assessment of morphologic leukemia free state (MLFS) and partial remissions by bone marrow aspirate
timeFrame: 180 days
measure: Assessment of blast count reductions by complete blood counts using peripheral blood
timeFrame: 180 days
measure: To determine progression-free survival (PFS), overall survival (OS), and duration of response
timeFrame: 180 days
Other outcomes:
measure: Exploratory objective to correlate treatment response with cytogenetic characteristics
timeFrame: 30 days
measure: Exploratory objective to correlate treatment response with molecular characteristics
timeFrame: 30 days
Locations:
city: La Jolla
country: United States
facility: Scripps Green Hospital
state: California
city: Los Angeles
country: United States
facility: UCLA Medical Center
state: California
city: New York
country: United States
facility: Weill Cornell Medical College - NewYork-Presbyterian Hospital
state: New York
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: Weill Cornell Medical College - New York-Presbyterian Hospital
name: Gail J Roboz, MD
role: PRINCIPAL_INVESTIGATOR
References: